

MENTORING RECEPTION

Hosted by Molecular and Systems Biology (MSBSS), Mechanisms, and In Vitro and Alternative Methods (IVAM) Specialty Sections

Additional sponsorship by: Career Resource and Development Committee (CRAD)

WHEN

Tuesday March 13, 2018
6:30 – 8:30 PM

WHERE

Casa Rio, 430 E Commerce St, San Antonio, TX
5 min. walk from the Convention Center!



WHAT

Trainees will have the opportunity to network with leading toxicology experts from industry, academia, government, and non-profit organizations. Heavy hors d'oeuvres and 1 drink ticket/person will be provided.

Space is limited! Register [here!](#)



MENTORS

INDUSTRY

Rhiannon Hardwick, PhD

Research Scientist
Theravance BioPharma

Pam Spencer, PhD

Senior Director of Regulatory Affairs &
Product Stewardship
ANGUS Chemical Company

Marie Fortin, PhD

Sr. Manager for Toxicology
Alcami Corporation

Joe Cichocki, PhD

Scientist, Toxicology
Alnylam Pharmaceuticals

Ruth Roberts, PhD

Chair of Drug Discovery at Birmingham
University, UK
Cofounder of Apconix

Tao Wang, MD, PhD

Director of Toxicology
Achaogen

CONSULTING

Robyn Prueitt, PhD

Senior Toxicologist
Gradient

Rob DeWoskin, PhD

Principal
etiologic, LLC

Julie Goodman, PhD

Principal
Gradient

NON-PROFIT

Amy Clippinger, PhD

Director
PETA International Science Consortium
Ltd

ACADEMIA

Dana Dolinoy, PhD

Chair and Associate Professor
University of Michigan School of Public
Health

Marc Gillespie, PhD

Associate Dean Graduate Education &
Research
St. John's University

Alicia Timme-Laragy, PhD

Assistant Professor
University of Massachusetts Amherst

Heather Wallace, PhD

Professor
University of Aberdeen

Kenneth Ramos, MD, PhD

Associate Vice President, Precision
Health Sciences
University of Arizona Health Sciences

Larissa Williams, PhD

Assistant Professor
Bates College

Angela Slitt, PhD

Associate Professor
University of Rhode Island

GOVERNMENT

Shaun McCullough, PhD

Principal Investigator
U.S. Environmental Protection Agency

Tamara Tal, PhD

Principal Investigator/Biologist
U.S. Environmental Protection Agency

Warren Casey, PhD

Director
NIEHS/ NTP/NICEATM

INDUSTRY



Rhiannon Hardwick, PhD

Research Scientist
Theravance BioPharma
rhardwick@theravance.com

I currently serve as a project toxicologist for discovery phase project teams and am responsible for assessing target safety, guiding lead candidate safety optimization, and establishing safety criteria for successful candidate nomination. I previously worked as a liver biologist and tissue engineer for a 3D bioprinting company and as team lead was responsible for development of market-driven model improvements, management of custom liver model design and evaluation, and leading collaborative cross-functional investigative initiatives. My graduate training and postdoctoral work centered in liver disease and mechanistic parameters that may lead to patient susceptibility to hepatotoxicity.



Pam Spencer, PhD

Senior Director of Regulatory Affairs & Product Stewardship
ANGUS Chemical Company
pjspencer@angus.com

Dr. Pamela Spencer is the Senior Director of Regulatory Affairs and Product Stewardship at ANGUS Chemical Company, in Chicago, IL. Prior to this role, she worked for the Dow Chemical Company for 30 years, retiring as the Scientific Director of Dow's Toxicology Environmental Research & Consulting function.



Marie Fortin, PhD

Sr. Manager for Toxicology
Alcami Corporation
marie.c.fortin@gmail.com

Board-certified and European-registered toxicologist versed in risk assessment. Experienced in product safety and occupational health in both consumer goods and pharmaceutical industries. Knowledgeable in pharmacology, PD/PK, and familiar with FDA and ICH regulations and guidelines.

INDUSTRY



Joe Cichocki, PhD

Scientist, Toxicology
Alnylam Pharmaceuticals
jcichocki@alnylam.com

I have been a Toxicologist at Alnylam Pharmaceuticals for approximately one year. In my first post-doc role, I provide nonclinical support to multiple program teams in order to develop RNAi therapeutics for various indications, including genetic, cardio-metabolic, and hepatic infectious diseases. While most of my tasks involve report writing, including co-authoring nonclinical sections of regulatory dossiers, I also serve as the Regulatory Toxicology liaison to the Investigative Sciences group, which is a great way to stay immersed in the science.



Ruth Roberts, PhD

Chair of Drug Discovery at Birmingham University, UK
Cofounder of Apconix
ruth.roberts@apconix.com

Ruth is chair of drug discovery at Birmingham University, UK and Cofounder of Apconix, an integrated toxicology and ion channel company. Before that Ruth was Global Head of Regulatory Safety at AstraZeneca and Director of Toxicology for Aventis in Paris, France. With >140 publications in peer reviewed journals, Ruth is president elect of ATS, former president of the British Toxicology Society, current secretary to SOT and former president of EUROTOX.



Tao Wang, MD, PhD

Director of Toxicology
Achaogen
twang@achaogen.com


Dr. Wang is Director of Toxicology at Achaogen, Inc., where she has responsibility for all toxicology functions across early and late stage development programs, including non-clinical safety strategies, operations, resourcing, budget & timelines. Prior to joining Achaogen, Dr. Wang worked at Novartis Pharmaceuticals for more than a decade, leading safety assessment efforts for oncology and non-oncology drug development projects.

CONSULTING



Robyn Prueitt, PhD
Senior Toxicologist
Gradient
rprueitt@gradientcorp.com

Toxicologist at an environmental consulting firm for more than 10 years. Provides expertise in evaluating toxicology data to support projects related to human health risk assessment, regulatory comment, and toxic tort litigation. Manages the firm's toxicology/epidemiology technical group.



Rob DeWoskin, PhD
Principal
etiologic, LLC
rdewoskin@etiologic.net

Over 35 years of laboratory and human health risk assessment (EPA and Research Triangle Institute; RTP, NC). Research focus is on normal and perturbed biological networks, biologically based computational models, and identification of preventive practices or optimal therapies for disease.



Julie Goodman, PhD
Principal
Gradient
jgoodman@gradientcorp.com

Dr. Goodman is a Principal at Gradient, an environmental consulting company. She is an expert in epidemiology and toxicology, and their application to human health risk assessment, and focuses on chemicals in consumer products, the workplace, and the environment, as well as pharmaceuticals. She recently was an adjunct faculty member in the Department of Epidemiology at the Harvard T. H. Chan School of Public Health, where she taught a class on meta-analysis, and, before joining Gradient, was a Cancer Prevention Fellow at the National Cancer Institute. Dr. Goodman has authored many original peer-reviewed research articles, review articles, and book chapters on a wide variety of topics, including systematic reviews of numerous chemicals and health outcomes, and has presented scientific analyses and findings to community groups, and regulatory and legislative bodies, and in the litigation setting.

ACADEMIA



Dana Dolinoy, PhD

Chair and Associate Professor
University of Michigan School of Public Health
ddolinoy@umich.edu

I serve as VP elect of MSBSS and as Chair of the Dept of Environmental Health Sciences at University of Michigan. I lead a research lab investigating the role of epigenetics in the developmental origins of disease. I enjoy reading and paddle boarding!



Marc Gillespie, PhD

Associate Dean Graduate Education & Research
St. John's University
gillespm@stjohns.edu

I hold a Ph.D. in Oncological Sciences from the University of Utah and am a Professor of Pharmaceutical Sciences & Dean of Graduate Education and Research at St. John's University, College of Pharmacy and Health Sciences. I serve as the Chair the Institutional Biosafety Committee and Chair the Committee On Outcomes And Assessment for the College. I am trained as a molecular biologist with specialties in protein biochemistry, bioinformatics, proteomics, and toxicology and work as a Biocurator and with the Reactome Project, a human centric pathway database of biological processes. I lead a research group focused on toxicogenomics, bioinformatics, and biomarker discovery.



Alicia Timme-Laragy, PhD

Assistant Professor
University of Massachusetts Amherst
aliciat@umass.edu

Tenure track assistant professor at R1 university for the past five years, currently going through tenure review. Balancing research, grants, teaching, papers, mentoring, and service, while raising a family.



Heather Wallace, PhD

Professor
University of Aberdeen
h.m.wallace@abdn.ac.uk

Heather is a full professor with a research and teaching portfolio. She is head of industrial liaison for the school of Medicine, Medical Science and Nutrition. Heather has experience of regulatory affairs through MHRA and Department of Health and via EFSA. She is President-Elect of EUROTOX and has recently been President of British Toxicology Society.

ACADEMIA



Kenneth Ramos, MD, PhD

Associate Vice President, Precision Health Sciences
University of Arizona Health Sciences
ksramos@email.arizona.edu

Kenneth S. Ramos, MD, PhD, is Professor of Medicine at the University of Arizona Health Sciences and Associate Vice President. He is an accomplished physician-scientist and transformational leader, with designations in the National Academy of Sciences and National Academy of Medicine. He has significant experience across the tripartite areas of education, research, and clinical service, and is recognized throughout the world for his contributions in the areas of genomics, precision medicine, and toxicology.



Larissa Williams, PhD

Assistant Professor
Bates College
lwillia2@bates.edu

I am a developmental toxicologist at a small liberal arts college in Maine. In addition to my teaching responsibilities, I run an active NSF- and NIH-funded lab with undergraduates.



Angela Slitt, PhD

Associate Professor
University of Rhode Island
angela_slitt@uri.edu

Associate professor in Pharmacology and toxicology studying mechanisms of liver disease and beneficial health effects of natural products. Expertise in liver and adipocyte assays.

GOVERNMENT



Shaun McCullough, PhD

Principal Investigator
U.S. Environmental Protection Agency
mccullough.shaun@epa.gov


I have a PhD in Biochemistry and Molecular Genetics from the University of Virginia and completed my postdoctoral training in the US Environmental Protection Agency's Clinical Research Branch prior to becoming a Principal Investigator in the EPA's National Health and Environmental Effects Research Laboratory. My research program explores the molecular mechanisms underlying susceptibility and exposure effects associated with air pollution exposure. Our efforts are focused around the use of in vitro primary cell models and clinical studies to identify the role of cellular signaling pathway activation, transcriptional regulation, and chromatin biology in toxicant-exposure effects relationships. Recently, we have also been developing 3D/organotypic in vitro models of the airway to add depth and biological context to our studies. In addition to my research, I am the Vice President of MSBSS, Chair of the Contemporary Concepts in Toxicology meeting "Building a Better Epithelium: Breaking the Barrier to the Next Generation of Toxicity Testing," and Co-Chair of SOT's Career Resources and Development Committee.



Tamara Tal, PhD

Principal Investigator/Biologist
U.S. Environmental Protection Agency
tal.tamara@epa.gov

Tamara Tal is a Principal Investigator in the Integrated Systems Toxicology Division at the U.S. Environmental Protection Agency (EPA). The Tal lab studies whether host-associated microbiota modifies the toxicity of environmental chemicals in zebrafish. Tamara received her doctorate degree in Toxicology from the University of North Carolina at Chapel Hill in 2008. She completed postdoctoral fellowships with Robert Tanguay at Oregon State University (2008-2011) and Stephanie Padilla at the U.S. EPA (2011-2015).



Warren Casey, PhD

Director
NIEHS/ NTP/NICEATM
warren.casey@nih.gov

I worked in pharma for 15 years (GSK), mostly focused on evaluating / utilizing new technology in the context of mechanistic toxicology to support pre-clinical safety assessments. I've been with the National Toxicology Program for the past 8 years, leading the group responsible for coordinating the evaluation of non-animal testing methods across the U.S. government and with international partners. Our group has been collaborating with NIH NCATS TissueChip and interagency Tox21 programs, with particular emphasis on identifying opportunities to put these technologies into everyday use.

NON-PROFIT



Amy Clippinger, PhD

Director

PETA International Science Consortium Ltd

amyjc@piscltd.org.uk

Dr. Amy Clippinger is the Director of the PETA International Science Consortium. She received her doctorate in Cellular and Molecular Biology and Genetics in 2009 from Drexel University College of Medicine and was a postdoctoral fellow in the Cancer Biology Department at the University of Pennsylvania from 2009 to 2012. In 2012, Dr. Clippinger joined the Science Consortium where she collaborates with industry, academia, and regulatory agencies to promote alternatives to animal testing. In this capacity, she has organized expert working groups, workshops, webinars, and published on topics including alternative approaches for acute systemic toxicity testing, inhalation toxicity testing, and REACH. She is the Immediate Past President of the Society of Toxicology's In Vitro and Alternative Methods Specialty Section.